Retraction to: Cellular & Molecular Biology Letters (2022) 27:28 https://doi.org/10.1186/s11658-022-00324-w
The Editor-in-Chief has retracted this article at the authors’ request. After publication, the authors became aware that the KYSE180 cells used in this study were cross-contaminated. Further checks by the publisher identified high similarity between the KYSE180 200 and 300 μM middle images. Additionally, the authors have stated that the number of injected cells for the in vivo tumor growth assay provided in the Materials and methods is incorrect.
All authors agree to this retraction.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Huang, HM., Huang, XY., Wu, SP. et al. Retraction Note to: Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1–AKT pathway. Cell Mol Biol Lett 27, 67 (2022). https://doi.org/10.1186/s11658-022-00369-x
Published:
DOI: https://doi.org/10.1186/s11658-022-00369-x